FABP4 and acute kidney injury: In our previous study, we found that FABP4 contributed to the pathogenesis of ischaemia/reperfusion‐ and rhabdomyolysis‐induced AKI and suggested that FABP4 inhibition might be a promising therapeutic strategy for AKI.23, 24 In the study, we aimed to explore whether pharmacological and genetic inhibition of FABP4 alleviated cisplatin‐induced AKI and to determine the involved mechanisms.